

# Belgian Thyroid Club

3<sup>rd</sup> December 2011



## Thyroid and the Thymus

Vincent GEENEN, MD, PhD  
*Research Director at F.R.S.-FNRS (Belgium)*  
University of Liege – GIGA-I<sup>3</sup> Immunendocrinology



# The moving place of the thymus in the history of medicine

**Claude Galen** – 2<sup>nd</sup> 'father' of Western medicine (129 – 210 or 216 AD)




« *The thymus is the seat of soul, eagerness and fortitude.* »

«*Troubles thymiques*» in French medical language  
= mood disorders, i.e. bipolar and unipolar depression.

The new views as to the morphology of the thymus gland and their bearing on the problem of the function of the thymus. **JA Hammar** (1921) *Endocrinology* **5**: 43-73.


« *The cases in which hyperplasia of the thymus is found are relatively rare. Such findings have been made chiefly after castration, in Graves' disease, myasthenia and acromegaly.* »




Role of the thymus in murine leukaemia. **JFAP Miller** (1959) *Nature* **183**: 1069.

Immunological function of the thymus. **JFAP Miller** (1961) *Lancet* **2**: 748-9.

# Integrated evolution of the immune and neuroendocrine systems




# T-cell differentiation in the thymus



# Thymic repertoire of neuroendocrine *self* precursors


| <b>FAMILY</b>                              | <b>THYMIC SELF ANTIGENS</b>            |
|--|--|
| <b><i>Neurohypophysial peptides</i></b>    | Oxytocin / OT<br>(>> Vasopressin / VP) |
| <b><i>Neurotensin/<br/>Neuromedins</i></b> | Neurotensin / NT                       |
| <b><i>Tachykinins</i></b>                  | Neurokinin A                           |
| <b><i>Natriuretic peptides</i></b>         | ANP                                    |
| <b><i>Somatostatins</i></b>                | Cortistatin                            |
| <b><i>Insulin family</i></b>               | IGF-2<br>(> IGF-1 > Insulin)           |

# Thymic expression of tissue-restricted antigens (TRA)




Nature Reviews | Immunology

# TSHR expression in the thymus



# Thymic expression of thyroid antigens



Sospedra J. *et al.* (1998) *J Immunol* **161**: 5918-5929

Dutton *et al.* (1997) *Thyroid* **6**: 879-884

Spitzweg *et al.* (1999) *Thyroid* **9**: 133-141

## Graves' Disease and Massive Thymic Hyperplasia

Maria Raquel Carvalho, Teresa Dias, Fernando Baptista, and Isabel do Carmo

### Dear Editor:

Graves' disease is an autoimmune thyroid condition in which autoantibodies against the thyrotropin (TSH) receptor stimulate the autonomous production of thyroxine and triiodothyronine. It is characterized by diffuse goiter and thyrotoxicosis and may be accompanied by an infiltrative orbitopathy and dermatopathy. A seldom-recognized feature of this disease is thymic hyperplasia. We would like to highlight this association and consider the pitfalls that can occur when this is encountered by describing a patient with Graves' disease and massive thymus hyperplasia.

A 22-year-old woman presented with Graves' disease. Serum biochemistry revealed TSH receptor autoantibodies (TRAbs) 178 U/L (normal range: <10 U/L; RIA TRAK-assay [Brahms, patterns MRC LATS-B 65/22 and TSAb Who 90/672], TSH <0.01  $\mu$ U/mL (0.35–5.5  $\mu$ U/mL), free thyroxine 4.37 ng/dL (0.89–1.8 ng/dL), and free triiodothyronine 19.41 pg/mL (2.3–4.2 pg/mL). TSH, free triiodothyronine, and free thyroxine levels were determined by a chemiluminescent assay (ADVIA Centaur; Bayer). The patient had marked Graves' ophthalmopathy and an incidentally discovered anterior mediastinal mass (8 × 5 cm) with no invasive characteristics on magnetic resonance imaging (Fig. 1a, b). She was started on treatment with methimazole. There was marked improvement of her thyrotoxic state and concomitant reduction in the size of her thymus (Fig. 2a, b). The patient was treated with total thyroidectomy. Ten

months after surgery, the thymic mass regressed to its normal involuted size at this age—total reduction of 80% (Fig. 3a, b).

Thymic hyperplasia is a common and reversible feature in Graves' disease (1). There are no consistent data between thymic hyperplasia and other hyperthyroid states. It has been suggested that one-third of patients with Graves' disease have microscopic abnormalities in the thymus (2). In most cases, however, thymic enlargement is minimal. Indeed, massive enlargement of the thymus has been reported only infrequently in Graves' disease (1,3). The pathophysiology of thymic hyperplasia in this setting has not been fully determined. However, the fact that treatment of the hyperthyroid state in Graves' disease with concomitant decrease in TRAbs leads to regression of the dimensions of the thymus suggests that thymic hyperplasia is more likely to be the result of Graves' disease (4). Actually, Murakami *et al.* postulated that both an indirect action of the lowering of thyroid hormone levels and the lowering of TRAbs could induce reduction in the thymus size. It seems that antithyroid drugs, besides causing a blockade of thyroid hormone synthesis, can also have an immunosuppressive effect, namely, reducing TRAbs levels. The same authors have demonstrated the presence of TSH receptor in nonneoplastic thymic tissue, suggesting that this receptor may serve as an autoantigen (5). Their findings support the concept that TRAbs in Graves' disease stimulate that thymic receptor causing thymus enlargement as they induce goiter in Graves' disease.





FIG. 1. (a, b) Thoracic MRI (pretreatment). MRI, magnetic resonance image.


# Thymus and Graves disease




## CT-scan

- A. Control
- B. Before treatment
- C. After treatment



## TSHR



- 1. Thyroid
- 2-3. Thymus





- Northern
- 1. Thyroid
- 2-3. Thymus



## ICC for TSHR


- A. Thyroid
- B-D. Thymus

# Graves disease and thymus hyperplasia




# APS-I or APECED syndrome

- Very rare autosomal recessive disease
- *AIRE* identified on 21q22.3 (positional cloning)
- 14 exons, transcription factor of 545 aa, > 45 mutations
- Maximal transcription in ***thymic epithelium***



# The thymus is essential for development of AIRE-associated autoimmunity





**C**


|                 | <u>Salivary</u> | <u>Retina</u> | <u>Stomach</u> |
|-----------------|-----------------|---------------|----------------|
| <b>WT Donor</b> | 0/4             | 0/4           | 0/4            |
| <b>KO Donor</b> | 3/5             | 2/5           | 3/5            |

A. Level of *Aire* expression in tissues

B-D. Transplantation of *Aire*<sup>-/-</sup> thymus



# Aire controls thymic transcription of tissue-specific Ags




# The role of the thymus in the development of autoimmunity


## *Thymus physiology*

- Intrathymic AIRE-mediated transcription of neuroendocrine and 'peripheral' genes (TSA).
- Deletion of T cells with high affinity for TSA.
- Selection of CD4<sup>+</sup> CD25<sup>+</sup> Foxp3<sup>+</sup> nTreg, specific of TSA.

*A defect in thymus T-cell education to self ?*




# TSHR mRNA expression in 17 human tissues





Colobran R et al. *Hum. Mol. Genet.* 2011;hmg.ddd247

# TSHR expression in the human thymus related to rs179247




Colobran R et al. *Hum. Mol. Genet.* 2011;hmg.ddd247

# TSHR expression in thymic cell populations



Colobran R *et al. Hum. Mol. Genet.* 2011;hmg.ddd247


# TTF1 expression in TSHR-expressing thymic cell populations




Colobran R et al. *Hum. Mol. Genet.* 2011;hmg.ddd247

# Transcription of *Insulin*-related genes in the thymus of BB rats

Diabetes-prone BB rats



# Impaired thymic tolerance to $\alpha$ -myosin directs autoimmune myocarditis



# The role of the thymus in the development of autoimmunity

## *Thymus physiology*


- Intrathymic AIRE-mediated transcription of neuroendocrine and 'peripheral' genes (TSA).
- Deletion of T cells with high affinity for TSA.
- Selection of CD4<sup>+</sup> CD25<sup>+</sup> Foxp3<sup>+</sup> nTreg, specific of TSA.

## *Thymus physiopathology*

- Absence or decrease in thymic expression/presentation of TSA (APECED, Down syndrome, BB rat, NOD...)
- Enrichment of T-cell repertoire with 'forbidden' self-reactive T cells (Teff).
- Decrease in selection of nTreg with specificity TSA.

## *Bridge between self-reactive Teff and peripheral autoantigens*

- Role of intra- and extra-MHC loci.
- Role of environmental factors (viruses, diet, vitamin D deficiency, stress...).



# General conclusions

## « Take-home message »

- ✓ A thymus dysfunction in T-cell education to self-antigens is the primary event in the development of organ-specific autoimmunity (such as autoimmune thyroiditis).
- ✓ Since T-cell self-education occurs during fetal development, most of autoimmune diseases are programmed during fetal life.
- ✓ Resulting from this thymic defect in T-cell self-education, the enrichment of T-cell repertoire with self-reactive T cells and its deficiency in self-specific nTreg is a condition **necessary but not sufficient** for priming the autoimmune response.

# Acknowledgments



## **ULg – Center of Immunology – GIGA-R**

Henri Martens, PhD  
Olivier Dardenne, PhD  
Isabelle Hansenne, PhD  
Lindsay Goffinet, BSc  
Gwennaëlle Bodart, BSc  
Alisson Beckers, BSc  
Marie Mottet, BSc  
Virginie Gridelet, BSc  
Chantal Renard, Tech  
Sophie Perrier d'Hauterive, MD, PhD  
Vincent Geenen, MD, PhD



## **UCL – Division of Cardiothoracic Surgery**

Jean Rubay, MD, PhD



RÉGION WALLONNE

**Waleo 3 - Tolediab**

**First Spin-off - ThymUP**



**Pfizer Independent Research Grant**

